Full-Time

Senior Scientist

NewLimit

NewLimit

51-200 employees

Develops epigenetic medicines to extend healthspan

Compensation Overview

$130k - $180k/yr

San Bruno, CA, USA

In Person

Category
Biology & Biotech (2)
,
Required Skills
Machine Learning
Cell Biology
Biochemistry
Data Analysis
Requirements
  • Ph.D. in cell biology, molecular biology, biochemistry or a related field or equivalent industry experience (5+ years)
  • Experience with primary cell isolation and functional characterization
  • Experience working with mouse models (e.g. kidney, cardiovascular, or cognitive disease models)
  • Experience with transgenic manipulation of primary cells either ex vivo or in vivo (e.g. using viral vectors, nucleic acid delivery)
Responsibilities
  • Develop functional assays and pre-clinical models to measure endothelial cell function
  • Collaborate with our Functional Genomics and Predictive Modeling teams to test reprogramming hypotheses at scale
  • Measure the impact of mRNA reprogramming medicines on endothelial cell function
  • Engineer in vivo nucleic acid delivery methods for endothelial cells
  • Analyze and interpret experimental data to drive pre-clinical decision making
Desired Qualifications
  • History of contributing to a drug development program at the pre-clinical or clinical development stage
  • Experience leading the design and execution of pre-clinical studies in mouse models
  • Experience with single cell genomics methods
  • Experience with pooled screening approaches using bulk or single cell read-outs (e.g. CRISPR fitness screens, Perturb/CROP-seq)

NewLimit develops medicines that aim to extend healthy years by reprogramming the epigenome of aging cells. It works by identifying aging-related epigenetic changes using single-cell genomics, machine learning, and high-throughput functional assays, then creating interventions to reverse those changes in targeted tissues such as the immune system and liver. Compared with others, NewLimit combines a specific focus on epigenetic reprogramming with a data-driven, tissue-targeted pipeline and pursues partnerships with pharma and biotech players to develop its proprietary medicines. Its goal is to deliver a new class of medicines that significantly increases the healthspan for patients with age-related diseases.

Company Size

51-200

Company Stage

Series C

Total Funding

$650M

Headquarters

South San Francisco, California

Founded

2022

Simplify Jobs

Simplify's Take

What believers are saying

  • $435 million Series C funds clinical entry and computational expansion.
  • Lead liver program targets alcohol-related liver disease with clear translational endpoints.
  • Platform expansion into immune and vascular cells broadens addressable aging indications.

What critics are saying

  • First-in-human liver reprogramming data arrive late, extending validation uncertainty.
  • Epigenetic reprogramming can trigger tumorigenicity or permanent cell-identity loss.
  • Lipid nanoparticle RNA delivery can fail before biology reaches human cells.

What makes NewLimit unique

  • AI-guided transcription factor screening compresses reprogramming discovery cycles.
  • Lead liver program uses lipid nanoparticle RNA medicines for transient expression.
  • Single-cell genomics and functional assays form an iterative closed-loop platform.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at NewLimit who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Parental Leave

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

2%
Intellectia.AI
Jan 6th, 2026
Coinbase CEO Armstrong's NewLimit raises $45M at $1.62B valuation for anti-aging research

NewLimit, an anti-aging startup founded in 2021 by Coinbase CEO Brian Armstrong, has raised $45 million in new funding, valuing the company at $1.62 billion. The round comes just five months after its Series B, demonstrating rapid growth and strong investor confidence. The company focuses on extending human healthspan by treating age-related diseases. The fresh capital will support groundwork for future clinical studies to advance its technological capabilities. Competition in the longevity sector is intensifying, with OpenAI CEO Sam Altman investing $180 million in rival Retro Biosciences. Despite a 2025 downturn in anti-aging research stocks, NewLimit's successful funding round highlights investor belief in the sector's long-term potential and suggests continued capital flow into this emerging market.

NewLimit
Oct 22nd, 2025
NewLimit has raised an additional $45M from Lilly, Duke University, Section 32, & Abstract on a $1.62B cap

Five months after closing our Series B, NewLimit has raised an additional $45M from Eli Lilly and Company, Duke Management Co, Section 32, and others on a $1.62B cap.

Endpoints News
Oct 20th, 2025
NewLimit Raises $45M with Eli Lilly

NewLimit, an anti-aging biotech startup co-founded by a cryptocurrency billionaire, has raised $45 million from new investors, including Eli Lilly. This funding positions NewLimit to potentially become biotech's latest unicorn.

TradingView
May 15th, 2025
NewLimit Raises $129.8M in Equity Financing

NewLimit has successfully raised $129.8 million in equity financing from a total offering amount of $130 million.

NewLimit
May 7th, 2025
NewLimit raises $130 million Series B led by Kleiner Perkins alongside NFDG, Khosla Ventures, Human Capital and others

NewLimit is developing medicines to extend human healthspan through epigenetic reprogramming